Iijima S, Sugita Y, Teshima Y, Hishikawa Y
Sleep. 1986;9(1 Pt 2):265-8. doi: 10.1093/sleep/9.1.265.
Mazindol, a new anorexiant, was administered at a daily dose of 0.5-4 mg to 10 narcoleptic subjects aged 21-63 years. All the patients suffered from sleep attacks and one or more of the REM-related symptoms. Eight patients received only mazindol, and two patients received mazindol simultaneously with clomipramine or flurazepam. Sleep attacks were reduced in nine patients, and cataplexy was also markedly reduced in four patients. Mild adverse reactions were reported in six patients: two patients complained of headache, four of nocturnal sleep disturbance, and two of reduced appetite. Most side effects disappeared spontaneously or after dose reduction, and none of the patients had to stop medication. The results suggest that mazindol is effective not only for sleep attacks but also for cataplexy. It is recommended as a treatment for mild cases of narcolepsy.
新型食欲抑制剂马吲哚以每日0.5 - 4毫克的剂量给予10名年龄在21至63岁的发作性睡病患者。所有患者均有睡眠发作及一种或多种与快速眼动睡眠相关的症状。8名患者仅接受马吲哚治疗，2名患者在服用马吲哚的同时还服用了氯米帕明或氟西泮。9名患者的睡眠发作减少，4名患者的猝倒症状也明显减轻。6名患者报告有轻度不良反应：2名患者抱怨头痛，4名患者有夜间睡眠障碍，2名患者食欲减退。大多数副作用在自行缓解或减量后消失，没有患者必须停药。结果表明，马吲哚不仅对睡眠发作有效，对猝倒也有效。推荐用于治疗轻度发作性睡病。
